- Home
- WHWK vs INCR Comparison
WHWK vs INCR Comparison
Compare WHWK & INCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WHWK | INCR |
|---|---|---|
| Founded | 2007 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.2M | 79.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | WHWK | INCR |
|---|---|---|
| Price | $2.72 | $0.94 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 108.0K | 75.4K |
| Earning Date | 02-24-2026 | 02-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $14,384,000.00 | ★ $72,158,312.00 |
| Revenue This Year | N/A | $69.54 |
| Revenue Next Year | N/A | $41.75 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.39 | $0.68 |
| 52 Week High | $3.77 | $1.78 |
Technical Indicators
Market Signals| Indicator | WHWK | INCR |
|---|---|---|
| Relative Strength Index (RSI) | 52.12 | 36.26 |
| Support Level | $2.60 | $0.90 |
| Resistance Level | $2.83 | $0.97 |
| Average True Range (ATR) | 0.19 | 0.04 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 41.47 | 35.63 |
Price Performance
Historical ComparisonAbout WHWK Whitehawk Therapeutics Inc.
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.
About INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.